A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Rasagiline

A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses (0.5, 1.0, and 2.0 mg) of Rasagiline Administered to Healthy Japanese and Caucasian Subjects

This study is designed to evaluate the pharmacokinetics of rasagiline in healthy Japanese and Caucasian subjects after single and multiple doses of rasagiline.

Study Overview

• Status: Completed
• Conditions: Parkinson's Disease
• Intervention / Treatment: Drug: Rasagiline; Drug: Placebo

Detailed Description

This is a single-center, double-blind, placebo-controlled, randomized study in healthy Japanese and Caucasian subjects after administration of single and multiple doses of rasagiline. All subjects will have a screening visit within 28 days of their check-in day (day -1) to confirm eligibility. Eligible subjects will be admitted to the investigational center on study day -1 and their eligibility to participate in the study confirmed. On the morning of day 1, subjects will be randomly assigned to receive a daily dose of 0.5, 1, or 2 mg of rasagiline or placebo at the same time every morning after an overnight fast (of at least 10 hours) on days 1 through 10. Venous blood samples (4 mL each) for pharmacokinetic analysis will be collected at specified time points through 24 hours after study drug administration on day 1 and through 48 hours after study drug administration on day 10. The duration of study participation for each subject will be approximately 6 weeks.

• Study Type: Interventional
• Enrollment (Actual): 64
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • California
    • Glendale, California, United States
      • Teva Investigational Site 10738

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years to 50 years (ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. The subject is able to read, speak, and write in English or Japanese, as applicable.
2. The subject is able to understand and be willing to comply with the study requirements (eg, all dietary, exercise, tobacco, and alcohol restrictions) and provide written informed consent to participate in the study.
3. The subject is a man or woman, 20 to 50 years of age, inclusive.
4. The subject has a body mass index (BMI) of 18.0-28.0 kg/m2, inclusive.
5. The subject is in a good health, as determined by medical history, ECG, vital signs, physical examination, and clinical laboratory tests.
6. If female and of childbearing potential, the subject must have a negative β-hCG test at screening and a negative urine human chorionic gonadotropin (HCG) test at check-in and be willing and able to use one of the following medically acceptable double barrier methods of birth control from the screening visit through the end-of-study visit: non-hormonal intrauterine device with condom, diaphragm with condom, or condom with spermicide. Female subjects who are postmenopausal (1 year since last menses) must have elevated follicle stimulating hormone (FSH) level above 35 U/L, or be surgically sterile.
7. The subject must complete the screening process within 4 weeks before study drug administration.

8. The subject must be willing and able to comply with study restrictions and to remain at the clinic for the required duration during the study period, and willing to return to the clinic for the follow-up evaluation, as specified in this protocol.

   Additional inclusion criteria for Japanese subjects:

9. The subject was born in Japan and holds a valid Japanese passport.
10. The subject has 2 Japanese parents and 4 Japanese grandparents, as confirmed by interview.

11. The subject has been living outside of Japan for 10 years or fewer as confirmed by interview.

    Additional inclusion criterion for Caucasian subjects:

12. The subject has no parents or grandparents of Japanese descent as confirmed by interview.

Exclusion Criteria:

1. The subject is a woman who is pregnant or lactating.
2. The subject has significant food or drug allergies or a known allergy or sensitivity to rasagiline or its derivatives or the formulation excipients.
3. The subject is unwilling to refrain from vigorous exercise (eg, strenuous or unaccustomed weight lifting, running, bicycling, etc) from 7 days before the first day of study drug administration until the final assessment.

4. The subject has had 1 of the following conditions in the noted amount of time before screening or at any time between screening and the first day of study drug administration:

   • major trauma or surgery in the last 2 months
   • acute infection in the last 2 weeks
   • malignancy within the last 5 years
5. The subject has a history of tuberculosis.
6. The subject has any condition that may interfere with drug absorption, distribution, metabolism, or excretion.
7. The subject is suffering from, or has a clinically significant history of, 1 or more of the following: cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, neurological, immunological, or psychiatric disorder(s), or a history of any illness that, in the opinion of the investigator, might confound the results of the study or pose additional risk to the subject if he or she participates in the study.
8. The subject has a positive test for hepatitis B surface antigen (HBsAg), hepatitis C antibody, or human immunodeficiency virus (HIV) antibody.
9. The subject has a history of hypertension or occasional increase of blood pressure, or any history of vascular structural abnormality.
10. The subject has a sitting blood pressure outside the range of 80 to 139 mm Hg (systolic) or 45 to 89 mm Hg (diastolic) (after at least a 5-minute rest) measured at screening. Blood pressure may be retested twice at intervals of 5 minutes. The blood pressure is considered sustained if either the systolic or diastolic pressure exceeds the stated limits in all 3 assessments.

11. The subject has used 1 of the following prohibited drugs or foods:

    • an investigational drug (new chemical entity) during the month prior to the first day of study drug administration
    • antidepressants, including selective serotonin reuptake inhibitors, tricyclic and tetracyclic antidepressants, within 42 days before the first day of study drug administration
    • MAO inhibitors, including reserpine and methyldopa, within 3 months prior to the first day of study drug administration
    • any medications (including over-the-counter [OTC] medications, vitamins, or herbal or nutritional supplements) within 14 days before the first day of study drug administration (except paracetamol/acetaminophen or ibuprofen used occasionally, up to 24 hours before the first day of study drug administration)
    • drugs known to significantly inhibit CYP1A enzyme drug metabolism within 14 days before the first day of study drug administration or drugs known to significantly induce human cytochrome P enzyme (CYP)1A drug metabolism within 28 days before the first day of study drug administration
    • excessive amounts of alcohol, defined as more than 3 drinks of alcoholic beverages (eg, beer, wine, or distilled spirits) per day in the last 3 months before the first day of study drug administration or a history of alcohol abuse
    • excessive amounts (equivalent to more than 6 cups of brewed coffee per day) of coffee, tea, cola, or other caffeinated beverages in the 3 months before the first day of study drug administration
    • grapefruit, Seville oranges, pomelo, or products made from them within 14 days before the first day of study drug administration until after the last day of pharmacokinetic sampling.
    • Other exclusion criteria apply.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: QUADRUPLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Rasagiline; Rasagiline mesylate oral tablets (AZILECT®) are provided at dose strengths of 0.5 and 1 mg (based on rasagiline base). Rasagiline oral tablets will be dispensed for 10 consecutive days of treatment. The oral dose will be administered each day with 240 mL water at room temperature after an overnight fast of at least 10 hours.	Drug: Rasagiline; Each subject will be enrolled into 1 of 4 cohorts: cohort 1 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo; cohort 2 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo; cohort 3 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo; cohort 4 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo Each subject will then be randomly assigned to 1 of the following groups: rasagiline at 0.5 mg (8 Japanese and 8 Caucasian subjects); rasagiline at 1 mg (8 Japanese and 8 Caucasian subjects); rasagiline at 2 mg (8 Japanese and 8 Caucasian subjects); placebo (8 Japanese and 8 Caucasian subjects); Other Names: rasagiline mesylate; TVP1012; AZILECT®
PLACEBO_COMPARATOR: Placebo; Placebo tablets match in size and appearance to rasagiline tablets for each dose strength. Placebo tablets will be dispensed for 10 consecutive days of treatment. The oral dose will be administered each day with 240 mL water at room temperature after an overnight fast of at least 10 hours.	Drug: Placebo; Each subject will be enrolled into 1 of 4 cohorts: cohort 1 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo; cohort 2 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo; cohort 3 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo; cohort 4 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo Each subject will then be randomly assigned to 1 of the following groups: rasagiline at 0.5 mg (8 Japanese and 8 Caucasian subjects); rasagiline at 1 mg (8 Japanese and 8 Caucasian subjects); rasagiline at 2 mg (8 Japanese and 8 Caucasian subjects); placebo (8 Japanese and 8 Caucasian subjects)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cmax		At Baseline through Day 10
Tmax		At Baseline through Day 10
AUC from time 0 to the time of the last measurable drug concentration (AUC0-t)	AUC 0-t will be calculated after administration of a single dose of rasagiline.	At Baseline to Day 1
AUC from time 0 to infinity (AUC∞)	AUC∞ will be calculated after administration of a single dose of rasagiline.	At Baseline to Day 1
Percentage extrapolated AUC (%AUCext)	%AUCext will be calculated after administration of a single dose of rasagiline.	At Baseline to Day 1
Apparent plasma terminal elimination rate constant (λz)		At Baseline to Day 10
Associated elimination half life (t½)		At Baseline to Day 10
AUC over the dosing interval at steady state (AUCτ)		At Baseline to Day 10
Minimum measured plasma concentration at steady state by inspection (Cmin,ss)	minimum measured plasma concentration at steady state by inspection (Cmin,ss) (multiple dose [predose concentrations on days 8 and 9]))	From Baseline to Day 10
Average plasma concentration at steady state (Cav,ss)	The average plasma concentration at steady state (Cav,ss) is obtained by the calculation: AUCτ/τ, where tau is the dosing interval	From Baseline to Day 10
Fluctuation at steady state	Fluctuation at steady state, calculated as (Cmax,ss-Cmin,ss)/Cav,ss	From Baseline to Day 10
Steady-state accumulation ratio (Rss)	Steady-state accumulation ratio (Rss) calculated as (AUCτ/AUC∞)	From Baseline to Day 10
Apparent total body clearance (CL/F)		From Baseline to Day 10
Apparent total volume of distribution (V/F)		From Baseline to Day 10

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Concentrations of 1-aminoindan	The concentrations of rasagiline major metabolite, 1-aminoindan, in plasma will be calculated, if possible.	Day 1 to Day 11
Peripheral monoamine oxidase B (MAOB)	The pharmacodynamics of rasagiline will be assessed by measuring the extent of peripheral monoamine oxidase B (MAOB) inhibition after multiple-dose administration of rasagiline, calculated as the percentage of the baseline platelet MAO-B activity.	Day 1 to Day 11
Occurrence of Adverse Events	Adverse events, clinical laboratory test results, vital signs measurements, physical examinations, 12- lead electrocardiogram (ECG) findings, and use of concomitant medications will be assessed throughout the study.	From informed consent signing to end of study (Day 12)

Collaborators and Investigators

• Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Study record dates

Study Major Dates

• Study Start: June 1, 2013
• Primary Completion (ACTUAL): September 1, 2013
• Study Completion (ACTUAL): November 1, 2013

Study Registration Dates

• First Submitted: June 13, 2013
• First Submitted That Met QC Criteria: June 13, 2013
• First Posted (ESTIMATE): June 18, 2013

Study Record Updates

• Last Update Posted (ESTIMATE): December 20, 2013
• Last Update Submitted That Met QC Criteria: December 19, 2013
• Last Verified: December 1, 2013

More Information

Terms related to this study

• Keywords: Parkinson's disease; Azilect; rasagiline mesylate
• Additional Relevant MeSH Terms: Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Parkinsonian Disorders; Basal Ganglia Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases; Parkinson Disease; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Neuroprotective Agents; Protective Agents; Monoamine Oxidase Inhibitors; Rasagiline
• Other Study ID Numbers: TVP1012-PK-10002